title: Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.
abstract: Fidaxomicin use to treat proven Clostridium difficile infection (CDI) was compared between 20 patients receiving care in critical care units (CCUs) and 30 patients treated on general medical floors. At baseline, the CCU patients had more initial CDI episodes, more severe and complicated disease, and more concurrent broad-spectrum antibiotic coverage. On multivariate analysis, the response to fidaxomicin therapy among the critically ill patients was comparable to that among patients in the general medical wards.
authors.affiliation: New York University Langone Medical Center and New York University School of Medicine, New York, New York.
authors.forename: Samuel
authors.initials: S
authors.lastname: Penziner
authors.affiliation: New York University Langone Medical Center and New York University School of Medicine, New York, New York.
authors.forename: Yanina
authors.initials: Y
authors.lastname: Dubrovskaya
authors.affiliation: New York University Langone Medical Center and New York University School of Medicine, New York, New York.
authors.forename: Robert
authors.initials: R
authors.lastname: Press
authors.affiliation: New York University Langone Medical Center and New York University School of Medicine, New York, New York amar.safdar@nyumc.org.
authors.forename: Amar
authors.initials: A
authors.lastname: Safdar
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000187:drug effects*; D003015:Clostridium Infections / Q000188:drug therapy*; D016638:Critical Illness; D005260:Female; D000077732:Fidaxomicin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010362:Patients' Rooms
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077732:Fidaxomicin